Plaque Psoriasis Clinical Trial
— FRONTIER 1Official title:
A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Verified date | January 2024 |
Source | Janssen Research & Development, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Status | Completed |
Enrollment | 255 |
Est. completion date | December 15, 2022 |
Est. primary completion date | December 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention - Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis - Participant has a total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline - Participant has a total Psoriasis area and severity index (PASI) >=12 at screening and baseline - Participant has a total Investigator global assessment (IGA) >=3 at screening and baseline Exclusion Criteria: - Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular) - Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) - Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab) - Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor [TNF]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention - Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention |
Country | Name | City | State |
---|---|---|---|
Canada | Dermatrials Research | Hamilton | Ontario |
Canada | Innovaderm Research | Montreal | Quebec |
Canada | Alliance Clinical Trials | Waterloo | Ontario |
Canada | XLR8 Medical Research | Windsor | Ontario |
France | Centre Hospitalier Le Mans | Le Mans | |
France | Hopital Charles Nicolle | Rouen | |
France | HIA Sainte Anne | Toulon | |
Germany | Fachklinik Bad Bentheim | Bad Bentheim | |
Germany | Charite - Universitaetsmedizin Berlin (CCM) | Berlin | |
Germany | ISA - Interdisciplinary Study Association GmbH | Berlin | |
Germany | Rothhaar Studien GmbH | Berlin | |
Germany | Niesmann & Othlinghaus GbR | Bochum | |
Germany | Rosenpark Research GmbH | Darmstadt | |
Germany | Universitatsklinikum Frankfurt | Frankfurt am Main | |
Germany | Derma-Study-Center Friedrichshafen GmbH | Friedrichshafen | |
Germany | MensingDerma research GmbH | Hamburg | |
Germany | Universitaetsklinikum Heidelberg | Heidelberg | |
Germany | Universitatsklinikum Schleswig Holstein Kiel | Kiel | |
Germany | Universitätsklinikum Leipzig AÖR | Leipzig | |
Germany | Dermatologische Gemeinschaftspraxis | Mahlow | |
Germany | Hautarztpraxis | Witten | |
Japan | Yamanashi Prefectural Central Hospital | Kofu | |
Japan | Miyata Dermatology Clinic | Matsudo | |
Japan | Takagi Dermatology Clinic | Obihiro-shi | |
Japan | Kume Clinic | Osaka Fu | |
Japan | Sapporo Skin Clinic | Sapporo | |
Japan | Shizuoka Prefectural General Hospital | Shizuoka | |
Japan | Shirasaki Dermatology Clinic | Takaoka | |
Japan | Kumamoto Kenhoku Hospital | Tamana | |
Japan | Toyama Prefectural Central Hospital | Toyama | |
Japan | Nomura Dermatology Clinic | Yokohama | |
Korea, Republic of | Pusan National University Hospital | Busan | |
Korea, Republic of | Seoul National University Bundang Hospital | Gyeonggi-do | |
Korea, Republic of | Konkuk University Medical Center | Seoul | |
Korea, Republic of | KyungHee University Hospital | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Poland | Nzoz Zdrowie Osteo-Medic | Bialystok | |
Poland | Dermed Centrum Medyczne Sp. z o.o | Lodz | |
Poland | DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski s.c. | Osielsko | |
Poland | Klinika Ambroziak Estederm Sp. z o.o | Warsaw | |
Poland | Wromedica | Wroclaw | |
Spain | Hosp. Univ. Germans Trias I Pujol | Barcelona | |
Spain | Hosp. Univ. 12 de Octubre | Madrid | |
Spain | Hosp. Provincial de Pontevedra | Pontevedra | |
Spain | Hosp. de Manises | Valencia | |
Spain | Hosp. Univ. I Politecni La Fe | Valencia | |
Taiwan | Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | National Taiwan University Hospital | Taipei City | |
Taiwan | Chang-Gung Memorial Hospital, LinKou Branch | Taoyuan | |
United Kingdom | Castle Hill Hospital | Cottingham | |
United Kingdom | Russell's Hall Hospital | Dudley | |
United Kingdom | Guy's and St Thomas' NHS Foundation Trust | London | |
United Kingdom | University Hospital Southampton NHS Foundation Trust | Southampton | |
United Kingdom | Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital | Wakefield | |
United States | Atlanta Dermatology, Vein & Research Center | Alpharetta | Georgia |
United States | Modern Research Associates | Dallas | Texas |
United States | Windsor Dermatology, PC | East Windsor | New Jersey |
United States | Hamzavi Dermatology | Fort Gratiot | Michigan |
United States | Center for Clinical Studies | Houston | Texas |
United States | Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana |
United States | Vivida Dermatology | Las Vegas | Nevada |
United States | Virginia Clinical Research | Norfolk | Virginia |
United States | Renstar Medical Research | Ocala | Florida |
United States | Austin Institute for Clinical Research | Pflugerville | Texas |
United States | Medical Dermatology Specialists | Phoenix | Arizona |
United States | University of Pittsburgh Department of Dermatology | Pittsburgh | Pennsylvania |
United States | Indiana Clinical Trial Center | Plainfield | Indiana |
United States | Oregon Dermatology and Research Center | Portland | Oregon |
United States | DermAssociates, PC | Rockville | Maryland |
United States | Arlington Dermatology | Rolling Meadows | Illinois |
United States | Pacific Skin Institute | Sacramento | California |
United States | Dermatology Associates | Seattle | Washington |
United States | Premier Clinical Research | Spokane | Washington |
United States | Forcare Clinical Research, Inc. | Tampa | Florida |
United States | Center for Clinical Studies | Webster | Texas |
Lead Sponsor | Collaborator |
---|---|
Janssen Research & Development, LLC |
United States, Canada, France, Germany, Japan, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16 | Percentage of participants achieving PASI 75 score (greater than or equal to [>=] 75 percentage [%] improvement from baseline in PASI) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. | Week 16 | |
Secondary | Change from Baseline in PASI Total Score at Week 16 | Change from baseline in PASI total score at Week 16 will be reported. | From baseline to Week 16 | |
Secondary | Percentage of Participants Achieving PASI 90 Score at Week 16 | Percentage of participants achieving PASI 90 score (>=90% improvement from baseline in PASI) at Week 16 will be reported. | Week 16 | |
Secondary | Percentage of Participants Achieving PASI 100 Score at Week 16 | Percentage of participants achieving PASI 100 score (100% improvement from baseline in PASI) at Week 16 will be reported. | Week 16 | |
Secondary | Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 | Percentage of participants who achieve an IGA score of cleared (0) or minimal (1) at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). | Week 16 | |
Secondary | Percentage of Participants Achieving an IGA Score of Cleared (0) at Week 16 | Percentage of participants who achieve an IGA score of cleared (0) at Week 16 will be reported. | Week 16 | |
Secondary | Change from Baseline in Body Surface Area (BSA) at Week 16 | Change from baseline in BSA at Week 16 will be reported. Body Surface Area is a commonly used measure of severity of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). | From baseline to Week 16 | |
Secondary | Change from Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16 | Change from baseline in PSSD symptoms scores at Week 16 will be reported. The PSSD includes patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two subscores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. | From baseline to Week 16 | |
Secondary | Change from Baseline in PSSD Signs Score at Week 16 | Change from baseline in PSSD signs score at Week 16 will be reported. | From baseline to Week 16 | |
Secondary | Percentage of Participants Achieving PSSD Symptoms Score=0 at Week 16 in Participants with a Baseline Symptoms Score >=1 | Percentage of participants achieving PSSD symptoms score=0 at Week 16 in participants with a baseline symptoms score >=1 will be reported. | Week 16 | |
Secondary | Percentage of Participants Achieving PSSD Sign Score=0 at Week 16 in Participants with a Baseline Sign Score >=1 | Percentage of participants achieving PSSD sign score=0 at Week 16 in participants with a baseline sign score >=1 will be reported. | Week 16 | |
Secondary | Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 16 in Participants with Baseline DLQI Score >1 | The DLQI is a dermatology-specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past 7 days and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. | Week 16 | |
Secondary | Change from Baseline in Patient-reported Outcomes Measurement Information System (PROMIS-29) Domain Score at Week 16 | Change from baseline in PROMIS-29 domain scores at week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL instrument assessing 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. These questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes. | From baseline to Week 16 | |
Secondary | Percentage of Participants Who Achieve >= 5-Point Improvement from Baseline in PROMIS-29 Domain Score at Week 16 | Percentage of participants who achieve >=5-point improvement from baseline in PROMIS-29 domain score at Week 16 will be reported. | Week 16 | |
Secondary | Number of Participants with Adverse Events (AEs) | An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | Up to 24 weeks | |
Secondary | Number of Participants with Serious Adverse Events (SAEs) | SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. | Up to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 |